Learn More
A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide (‘Casodex’) 150 mg/day therapy following radical therapy for prostate cancer assessed(More)
PURPOSE To evaluate the efficacy and tolerability of prophylactic breast irradiation in reducing the incidence and severity of bicalutamide-induced gynecomastia and breast pain. METHODS AND(More)
PURPOSE We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced(More)
PURPOSE We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer. MATERIALS AND(More)